Business
Moolec Science Achieves One of the Highest Commercial-Scale GLA Concentrations From U.S. GLASO1 Crushing
WARWICK, UK / ACCESS Newswire / February 13, 2026 / Moolec Science Limited, a wholly-owned subsidiary of Moolec Science SA (NASDAQ:MLEC)("the Company"; "Moolec"), an innovation-driven company engineering plants and microbes to unlock scalable protein ...
About this update from Moolec Science Sa
WARWICK, UK / ACCESS Newswire / February 13, 2026 / Moolec Science Limited, a wholly-owned subsidiary of Moolec Science SA (NASDAQ:MLEC)("the Company"; "Moolec"), an innovation-driven company engineering plants and microbes to unlock scalable protein solutions for the global food industry, today announced positive results from the crushing process of its U.S. GLASO1 safflower platform, confirming gamma-linolenic acid ("GLA") concentrations of approximately 45%. The results follow the successful completion of Moolec's 2025 U.S. GLASO1 safflower campaign and represent a major operational milestone, validating the Company's ability to deliver commercial-scale agricultural and industrial performance through its plant-engineered molecular farming platform. Crushing Results Confirm Commercial-Scale PerformanceFollowing harvest, safflower produced under the GLASO1 program was processed through standard U.S. crushing operations. Analysis confirmed: These results confirm that the GLASO1 platform performs reliably through the crushing stage at commercial scale, a critical validation step for scalable ingredient production. 2025 GLASO1 U.S. Campaign Highlights The 2025 campaign marked Moolec's first successful large-scale expansion of the GLASO1 platform, transitioning from prior development and smaller-scale deployments to full commercial agricultural execution. Strategic Positioning in the U.S. Nutrition & Supplements MarketThe high GLA concentration achieved through the GLASO1 platform significantly strengthens Moolec's positioning in the U.S. nutrition and dietary supplements market, where demand favors: Early engagement with U.S.-based market participants supports the Company's strategy of disciplined, execution-led growth anchored in validated performance rather than speculative scale-up. "The U.S. GLASO1 platform has reached an inflection point," said Alejandro Antalich, CEO at Moolec Science. Achieving approximately 45% GLA concentration at commercial scale confirms that our technology is not only scientifically differentiated, but operationally executable within existing U.S. agricultural and processing infrastructure." "We believe the approximately 45% GLA concentration achieved by GLASO1 places it among the highest-performing GLA-producing platforms reported at commercial scale. Thi...